본문 바로가기 주메뉴 바로가기 하단메뉴 바로가기

GC녹십자MS

  • Contact / Q&A
  • recruitment
  • KOREA
  • SITEMAP
  • Company Introduction
  • Product Information
  • R&D
  • CSR
  • INVESTORS
 

R&D

With the goal of achieving ‘customer-oriented R&D’, we are focusing on establishing future technologies by expanding and deepening existing technologies.

R&D Introduction

Print

GCMS Research Institute

Extensive Experience and Accumulated Know-How in Product Development and Commercialization
Intensified Research Infrastructure (GC Pharma Comprehensive Research Institute, GC Labs Pioneering Diagnosis, GC Cell etc.)

GSMS esearch Institute was established in 2001 as a corporate research center. Since obtaining a license for reagents of blood type determination in 1972, we have committed to the development of diagnostic reagents, including those for hepatitis B antigen and antibody in 1980s, the nation’s first diagnostic reagent for acquired immunodeficiency syndrome using enzyme immunoassay and the world’s first diagnostic reagent for epidemic hemorrhagic fever.

Since then, we have developed with our own technology and continuously released in vitro diagnostic reagents, such as ELISA, Rapid, MICT and Real-time PCR that can help diagnosis of various diseases including sexually transmitted infection, respiratory diseases, and febrile diseases as well as sex hormone-related diagnosis.